Filing Details

Accession Number:
0001209191-17-060706
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-14 17:52:40
Reporting Period:
2017-11-09
Accepted Time:
2017-11-14 17:52:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1704255 James Engelhart C/O Biohaven Pharmaceuticals, Inc.
234 Church Street
New Haven CT 06510
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Acquisiton 2017-11-09 21,600 $0.61 25,176 No 4 M Direct
Common Shares Disposition 2017-11-09 13,083 $26.26 12,093 No 4 S Direct
Common Shares Disposition 2017-11-09 8,517 $27.37 3,576 No 4 S Direct
Common Shares Acquisiton 2017-11-10 8,938 $0.61 12,514 No 4 M Direct
Common Shares Disposition 2017-11-10 8,938 $26.28 3,576 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Employee Stock Option (Right to Buy) Disposition 2017-11-09 21,600 $0.00 21,600 $0.61
Common Shares Employee Stock Option (Right to Buy) Disposition 2017-11-10 8,938 $0.00 8,938 $0.61
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
40,900 2024-11-25 No 4 M Direct
31,962 2024-11-25 No 4 M Direct
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.96 - $26.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.96 - $27.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.74 - $26.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
  5. The shares underlying this option vested as to 25% of the shares on November 26, 2014, with the remainder vesting in 3 equal installments on the first, second and third anniversaries of the grant date, subject to the reporting person's continued service as of each applicable vesting date.